Literature DB >> 25201618

Prostate cancer: androgen suppression duration and zoledronic acid: under the RADAR.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25201618     DOI： 10.1038/nrurol.2014.252

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.

Authors:  James W Denham; David Joseph; David S Lamb; Nigel A Spry; Gillian Duchesne; John Matthews; Chris Atkinson; Keen-Hun Tai; David Christie; Lizbeth Kenny; Sandra Turner; Nirdosh Kumar Gogna; Terry Diamond; Brett Delahunt; Christopher Oldmeadow; John Attia; Allison Steigler
Journal:  Lancet Oncol       Date:  2014-08-14       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.